Clarity Pharmaceuticals Submits Theranostic Investigational New Drug (IND) Application for Cu-64 SARTATE™ and Cu-67 SARTATE™ to the US FDA
Sydney, Australia 3 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic and therapy) trial with 64Cu-SARTATE™ and 67Cu-SARTATE™ in…